Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Common Equity (2019 - 2025)

Historic Common Equity for Lyell Immunopharma (LYEL) over the last 7 years, with Q3 2025 value amounting to $329.1 million.

  • Lyell Immunopharma's Common Equity fell 3798.33% to $329.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $329.1 million, marking a year-over-year decrease of 3798.33%. This contributed to the annual value of $382.8 million for FY2024, which is 4154.93% down from last year.
  • According to the latest figures from Q3 2025, Lyell Immunopharma's Common Equity is $329.1 million, which was down 3798.33% from $298.9 million recorded in Q2 2025.
  • Lyell Immunopharma's Common Equity's 5-year high stood at $1.0 billion during Q2 2021, with a 5-year trough of -$334.0 million in Q1 2021.
  • Over the past 5 years, Lyell Immunopharma's median Common Equity value was $697.6 million (recorded in 2023), while the average stood at $627.8 million.
  • Its Common Equity has fluctuated over the past 5 years, first skyrocketed by 52562.13% in 2021, then plummeted by 4723.35% in 2025.
  • Quarter analysis of 5 years shows Lyell Immunopharma's Common Equity stood at $929.8 million in 2021, then dropped by 10.38% to $833.3 million in 2022, then decreased by 21.4% to $655.0 million in 2023, then crashed by 41.55% to $382.8 million in 2024, then dropped by 14.03% to $329.1 million in 2025.
  • Its Common Equity stands at $329.1 million for Q3 2025, versus $298.9 million for Q2 2025 and $336.5 million for Q1 2025.